Antiviral efficacy and toxicity of ribavirin and foscarnet each given alone or in combination in the murine AIDS model

Toxicology and Applied Pharmacology

Volumn 143, Issue 1, 1997, Pages 140-151

  Omar, Rabeea F ^a   Harvie, Pierrot ^a   Gourde, Pierrette ^a   Désormeaux, André ^a   Tremblay, Michel ^a   Beauchamp, Denis ^a   Bergeron, Michel G ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FOSCARNET; RIBAVIRIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL MODEL; BLOOD TOXICITY; CONTROLLED STUDY; HYPERGAMMAGLOBULINEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPH NODE; MOUSE; NEPHROTOXICITY; NONHUMAN; SPLENOMEGALY;

ANIMALIA; MURINAE;

EID: 0031106033     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1996.8080     Document Type: Article

References (63)

1. Allen, L. B., Quenelle, D. C., Westbrook, L., Taylor, B. A., Prichard, M. N., Brazier, A. D., Hollingshead, M. G., and Shannon, W. M. (1995). In vitro and in vivo enhancement of ddl activity against Rauscher murine leukemia virus by ribavirin. Antiviral Res. 27, 317-323.
2. Baba, M., Pauwels, R., Balzarini, J., Herdewijn, P., De Clercq, E., and Desmyter, J. (1987). Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 31, 1613-1617.
3. Balzarini, J., Naesens, L., Robins, M. J., and De Clercq, E. (1990). Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside. J. Acquir. Immune Defic. Syndr. 3, 1140-1147.
4. Basham, T., Holdener, T., and Merigan, T. (1991). Intermittent, alternating, and concurrent regimens of zidovudine and 2′-3′ dideoxycytidine in the LP-BM5 murine induced immunodeficiency model. J. Infect. Dis. 163, 869-872.
5. Basham, T., Rios, D. C., Holdener, T., and Merigan, T. C. (1990). Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. J. Infect. Dis. 161, 1006-1009.
6. Beaufils, H., Deray, G., Katlama, C., Dohin, E., Henin, D., Sazdovitch, V., and Jouanneau, C. (1990). Foscarnet and crystals in glomerular capillary lumens. Lancet 336, 755.
7. Bergeron, M. G., Tsoukas, C. M., Roberts, R., Gent, M., Aoki, F., Conly, J., Falutz, J., Fanning, M., Fong, I. W., Garber, G., Gilmore, N., Landis, S., Macfadden, D. K., Mackie, I., Mansell, P., Marcoux, A., Montaner, J. S. G., Rachlis, A., Romanowski, B., Schlech, W., Sinave, C., Taylor, G., Toma, E., and the Canadian Study Group. (1991). Tolerance of ribavirine in early HIV disease. 7th International Conference on AIDS, Florence, June 16-21, Abstract MB2353.
8. Bergeron, M. G., Tsoukas, C. M., Securella, J., Aoki, F., Conly, J., Fanning, M., Fong, I. W., Garber, G., Gilmore, N., Landis, S., Macfadden, D. K., Mackie, I., Mansell, P., Marcoux, A., Montaner, J. S. G., Rachlis, A., Romanowski, B., Schlech, W., Sinave, G., Taylor, G., Toma, E., and the Canadian Study Group. (1992). Ribavirin in 462 patients with early HIV disease. 2nd Annual Canadian National Conference on HIV/AIDS, Vancouver, May 28-29, Abstract 65.
9. Bernier, R., Tremblay, M., Tsoukas, C., and Bergeron, M. G. 1997. Drug sensitivity of human immunodeficiency virus type-1 isolates after ribavirin therapy. J. Infect. Dis. 175, 176-178.
10. Cacoub, P., Deray, G., Baumelou, A., Le Hoang, P., Rozenbaum, W., Gentilini, M., Soubrie, C., Rousselie, R., and Jacobs, C. (1988). Acute renal failure induced by foscarnet: 4 cases. Clin. Nephrol. 29, 315-318.
11. Chrisp, P., and Clissold, P. (1991). Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41, 104-129.
12. Deray, G., Martinez, F., Katlama, C., Levaltier, B., Beaufils, H., Danis, M., Rozenheim, M., Baumelou, A., Dohin, E., Gentilini, M., and Jacobs, C. (1989). Foscarnet nephrotoxicity: Mechanism, incidence and prevention. Am. J. Nephrol. 9, 316-321.
13. Dusserre, N., Lessard, C., Paquette, N., Perron, S., Poulin, L., Tremblay, M., Beauchamp, D., Désormeaux, A., and Bergeron, M. G. (1995). Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, and pharmacokinetics. AIDS 9, 833-841.
14. Embretson, J., Zupancic, J., Ribas, J. L., Burke, A., Racz, P., Tenner-Racz, K., and Haase, A. (1993). Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362, 359-362.
15. Eriksson, B., and Schinazi, R. F. (1989). Combination of 3′-azido-3′deoxythymidine (Zidovudine) and phosphonoformate (Foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 33, 663-668.
16. Fernandez-Larsson, R., and Patterson, J. L. (1990). Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase. Mol. Pharmacol. 38, 766-770.
17. Fischl, M. A., Stanley, K., Collier, A. C., Arduino, J. M., Stein, D. S., Feinberg, J. E., Allan, J. D., Goldsmith, J. C., and Powdely, W. G. (1995). Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann. Intern. Med. 122, 24-32.
18. Fletcher, C. V., Collier, A. C., Rhame, F. S., Bennett, D., Para, M. F., Beatty, C. C., Jones, C. E., and Balfour, H. H. J. (1994). Foscarnet for suppression of human immunodeficiency virus replication. Antimicrob. Agents Chemother. 38, 604-607.
19. Gangemi, D. J., Nachtigal, M., Barnhart, D., Krech, L., and Jani, P. (1987). Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with Influenza or Herpes simplex virus. J. Inject. Dis. 155, 510-517.
20. Gazzinelli, R. T., Giese, N. A., and Morse, H. C., III (1994). In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J. Exp. Med. 180, 2199-2208.
21. Gilbert, B. E., and Knight, V. (1986). Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 30, 201-205.
22. Gilson, R. J. C., Semple, M., Gill, S. K., Loveday, C., Tedder, R. S., and Weller, I. V. D. (1992). Lack of suppression by ribavirin of HIV viraemia. Lancet 339, 1605-1606.
23. Goulden, M. G., Cammack, N., Hopewell, P. L., Penn, C. R., and Cameron, J. M. (1996). Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS 10, 101-102.
24. Hartley, J. W., Frederickson, T. N., Yetter, R. A., Makino, M., and Morse, H. C., III (1989). Retrovirus-induced murine acquired immunodeficiency syndrome: Natural history of infection and differing susceptibility of inbred mouse strains. J. Virol. 63, 1223-1231.
25. Harvie, P., Omar, R. F., Dusserre, N., Lansac, N., Désormeaux, A., Gourde, P., Simard, M., Tremblay, M., Beauchamp, D., and Bergeron, M. G. (1996a). Ribavirin potentiates the efficacy and toxicity of 2′,3′-dideoxyinosine in the murine acquired immunodeficiency syndrome model. J. Pharmacol. Exp. Ther. 279, 1009-1017.
26. Harvie, P., Omar, R. F., Dusserre, N., Désormeaux, A., Gourde, P., Tremblay, M., Beauchamp, D., and Bergeron, M. G. (1996b). Antiviral efficacy and toxicity of ribavirin in MAIDS model. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 12, 451-461.
27. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., and Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
28. Hoggard, P. G., Veal, G. J., Wild, M. J., Barry, M. G., and Back, D. J. (1995). Drug interactions with zidovudine phosphorylation in vitro. Antimicrob. Agents Chemother. 39, 1376-1378.
29. Hugin, A. W., Vacchio, M. S., and Morse, H. C., III (1991). A virus-encoded "superantigen" in a retrovirus-induced immunodeficiency syndrome of mice. Science 252, 424-427.
30. Husson, R. N., Mueller, B. U., Farley, M., Woods, L., Kovacs, A., Goldsmith, J. C., Ono, J., Lewis, L. L., Balis, F. M., Brouwers, P., Avramis, V. I., Church, J. A., Butler, K. M., Rasheed, S., Jarosinski, P., Venzon, D., and Pizzo, P. A. (1994). Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection. Pediatrics 93, 316-322.
31. Jacobson, M. A. (1992). Review of the toxicities of foscarnet. J. Acquir. Immune Defic. Syndr. 5(Suppl. 1), S11-S17.
32. Jacobson, M. A., Crowe, J., Levy, J., Aweeka, F., Gambertoglio, J., McManus, N., and Mills, J. (1988). Effects of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J. Infect. Dis. 158, 862-865.
33. Jacobson, M. A., Van der Horst, C., Causey, D. M., Dehlinger, M., Hafner, R., and Mills, J. (1991). In vivo anti-retroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG protocol 053). J. Infect. Dis. 163, 1219-1222.
34. Kende, M., Alving, C. R., Rill, W. L., Swartz, G. M., and Canonico, P. G. (1985). Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus in mice. Antimicrob. Agents Chemother. 27, 903-907.
35. Kim, W. K., Tang, Y., Kenny, J. J., Longo, D. L., and Morse, H. C., III (1994). In murine AIDS, B cells are early targets of defective virus and are required for efficient infection and expression of defective virus in T cells and macrophages. J. Virol. 68, 6767-6769.
36. Klinman, D. M., and Morse, H. C., III (1989). Characteristics of B cell proliferation and activation in murine AIDS. J. Immunol. 142, 1144-1149.
37. Larder, B. A., Kemp, S. D., and Harrigan, P. R. (1995). Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269, 696-699.
38. Masuda, A., Burton, G. F., Szakal, A. K., and Tew, J. G. (1995). Loss of follicular dendritic cells in murine-acquired immunodeficiency syndrome. Lab. Invest. 73, 511-520.
39. McCormick, J. B., Getchell, J. P., Mitchell, S. W., and Hicks, D. R. (1984). Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet 2, 1367-1369.
40. Montaner, J. S. G., and Schechter, M. T. (1995). A year of transformation in HIV/AIDS. Lancet 346, 12.
41. Morse, H. C., III, Chattopadhyay, S. K., Makino, M., Fredrickson, T. N., Hügin, A. W., and Hartley, J. W. (1992). Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 6, 607-621.
42. Nyberg, G., Svalander, C., Blohme, I., and Persson, H. (1989). Tubulointestinal nephritis caused by the antiviral agent foscarnet. Transplant Int. 2, 223-227.
43. Öberg, B. (1989). Antiviral effects of phosphonoformate. Pharmacol. Ther. 40, 213.
44. Omar, R. F., Dusserre, N., Désormeaux, A., Poulin, L., Tremblay, M., Beauchamp, D., and Bergeron, M. G. (1995). Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob. Agents Chemother. 39, 1973-1978.
45. Omar, R. F., Gourde, P., Désormeaux, A., Tremblay, M., Beauchamp, D., and Bergeron, M. G. (1996). In vivo toxicity of foscarnet and zidovudine each given alone or in combination. Toxicol. Appl. Pharmacol. 130, 324-332.
46. Palmer, S., Harmenberg, J., and Cox, S. (1996). Synergistic inhibition of human-immunodeficiency-virus isolates (including 3′-azida-3′-deoxythymidine-resistant isolates) by foscarnet in combination with 2′,3′-dideoxyinosine or 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 40, 1285-1288.
47. Pantaleo, G., and Fauci, A. S. (1994). Tracking HIV during disease progression. Curr. Op. Immunol. 6, 600-604.
48. Pantaleo, G., Graziosi, C., Demarest, J. F., Butini, L., Montroni, M., Fox, C. H., Orenstein, J. M., Kotler, D. P., and Fauci, A. S. (1993). HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358.
49. Pantaleo, G., Menzo, S., Vaccarezza, M., Graziosi, C., Cohen, O. J., Demarest, J. F., Montefiori, D., Orenstein, J. M., Fox, C., Schrager, L. K., Margolick, J. B., Buchbinder, S., Giorgi, J. V., and Fauci, A. S. (1995). Studies in subjects with long term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209-216.
50. Phillips, N. C., and Tsoukas, C. (1992). Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 79, 1137-1143.
51. Polis, M. A., DeSmet, M. D., Braid, B. F., Mellow, S., Falloon, J., Davey, R. T., Kovacs, J. A., Palestine, A. G., Nussenblatt, R. B., Masur, H., and Lane, H. C. (1993). Increased survival of a cohort of patient with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am. J. Med. 94, 175-179.
52. Richman, D. D., Meng, T.-C., Spector, S. A., Fischl, M. A., Resnick, L., and Lai, S. (1994). Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J. Acquir. Immune. Defic. Syndr. 7, 135-138.
53. Roberts, R. B., Hollinger, F. B., Parks, W. P., Rasheed, S., Laurence, J., Heseltine, P. N. R., Makuch, R. W., Lubina, J. A., Johnson, K. M., and the Ribavirin-LAS collaborative group. (1990). A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy: Virologic observations. AIDS 4, 67-72.
54. Rowe, W. P., Pugh, W. E., and Hartley, J. W. (1970). Plaque assay techniques for murine leukemia viruses. Virology 42, 1136-1139.
55. Sandström, E. G., Kaplan, J. C., Byington, R. E., and Hirsch, M. S. (1985). Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet 1, 1480-1482.
56. Schulman, N. R. (1984). Assessment of hematologic effects of ribavirin in humans. In Clinical Applications of Ribavirin (R. A. Smith, V. Knight, and J. A. D. Smith, Eds.), pp. 79-92. Academic Press, New York.
57. Senay, H., Trottier, S., Morissette, M., Gareau, L., Belles-Isles, M., Jutras, M., and Bergeron, M. (1991). Ribavirin therapy in patients in early stages of HIV infections. 7th International Conference on AIDS, Florence, June 16-21, Abstract WB 2105.
58. Shafer, R. W., Iversen, K. N., Winters, M. A., Aguiniga, E., Katzenstein, D., Merigan, T. C., and The AIDS Clinical Trials Group 143 Virology Team. (1995). Drug resistance and heterogenous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172, 70-78.
59. Smith, R. A., and Wade, M. (1986) Ribavirin: A broad spectrum antiviral agent. In Studies with a Broad Spectrum Antiviral Agent (Stapleton, Ed.), pp. 99-118. Royal Society of Medicine Services, London.
60. Thacore, H. R., Cunningham, R. K., Zhou, P., Nakeeb, S., Terzian, R., and Zaleski, M. B. (1994). Acquired immunodeficiency in murine lympho-proliferative disease: Considerations on pathogenesis. Immunobiology 190, 195-211.
61. Vogt, M. W., Hartshorn, K. L., Furman, P. A., Chou, T. C., Fyfe, J. A., Coleman, L. A., Crumpacker, C., Schooley, R. T., and Hirsh, M. S. (1987). Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235, 1376-1379.
62. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S., and Shaw, G. M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
63. Yarchoan, R., Lietzau, J. A., Nguyen, B.-Y., Brawley, O. W., Pluda, J. M., Saville, M. W., Wyvill, K. M., Steinberg, S. M., Agbaria, R., Mitsuya, H., and Broder, S. (1994). A randomized pilot study of alternative or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J. Infect. Dis. 169, 9-17.